LFA-1/ICAM-1 interaction is essential in support of inflammatory and specific T-cell regulated immune responses by mediating cell adhesion, leukocyte extravasation, migration, antigen presentation, formation of immunological synapse, and augmentation of T-cell receptor signaling. The increase of ICAM-1 expression levels in conjunctival epithelial cells and acinar cells was observed in animal models and patients diagnosed with dry eye. Therefore, it has been hypothesized that small molecule LFA-1/ICAM-1 antagonists could be an effective topical treatment for dry eye. In this letter, we describe the discovery of a potent tetrahydroisoquinoline (THIQ)-derived LFA-1/ICAM-1 antagonist (SAR 1118) and its development as an ophthalmic solution for treating dry eye.
The discovery and development of
targeted protein degraders have
become important areas of research in the field of medicinal chemistry.
Inducing degradation of a target protein presents several advantages
relative to simple inhibition including a potential for extended duration
of action and more profound pharmacology. While engineered heterodimeric
molecules have recently been a major focus within industry and academia,
this Perspective highlights examples of targeted protein degradation
observed for smaller, monomeric molecules. Methods and tools for evaluating
protein degradation as well as a discussion of physical properties
of monomeric vs engineered heterodimeric degraders are presented.
Because of their increased activity against activating mutants, first-generation epidermal growth factor receptor (EGFR) kinase inhibitors have had remarkable success in treating non-small-cell lung cancer (NSCLC) patients, but acquired resistance, through a secondary mutation of the gatekeeper residue, means that clinical responses only last for 8-14 months. Addressing this unmet medical need requires agents that can target both of the most common double mutants: T790M/L858R (TMLR) and T790M/del(746-750) (TMdel). Herein we describe how a noncovalent double mutant selective lead compound was optimized using a strategy focused on the structure-guided increase in potency without added lipophilicity or reduction of three-dimensional character. Following successive rounds of design and synthesis it was discovered that cis-fluoro substitution on 4-hydroxy- and 4-methoxypiperidinyl groups provided synergistic, substantial, and specific potency gain through direct interaction with the enzyme and/or effects on the proximal ligand oxygen atom. Further development of the fluorohydroxypiperidine series resulted in the identification of a pair of diastereomers that showed 50-fold enzyme and cell based selectivity for T790M mutants over wild-type EGFR (wtEGFR) in vitro and pathway knock-down in an in vivo xenograft model.
Activating
mutations within the epidermal growth factor receptor
(EGFR) kinase domain, commonly L858R or deletions within exon 19,
increase EGFR-driven cell proliferation and survival and are correlated
with impressive responses to the EGFR inhibitors erlotinib and gefitinib
in nonsmall cell lung cancer patients. Approximately 60% of acquired
resistance to these agents is driven by a single secondary mutation
within the EGFR kinase domain, specifically substitution of the gatekeeper
residue threonine-790 with methionine (T790M). Due to dose-limiting
toxicities associated with inhibition of wild-type EGFR (wtEGFR),
we sought inhibitors of T790M-containing EGFR mutants with selectivity
over wtEGFR. We describe the evolution of HTS hits derived from Jak2/Tyk2
inhibitors into selective EGFR inhibitors. X-ray crystal structures
revealed two distinct binding modes and enabled the design of a selective
series of novel diaminopyrimidine-based inhibitors with good potency
against T790M-containing mutants of EGFR, high selectivity over wtEGFR,
broad kinase selectivity, and desirable physicochemical properties.
The discovery of somatic Jak2 mutations in patients with chronic myeloproliferative neoplasms has led to significant interest in discovering selective Jak2 inhibitors for use in treating these disorders. A high-throughput screening effort identified the pyrazolo[1,5-a]pyrimidine scaffold as a potent inhibitor of Jak2. Optimization of lead compounds 7a-b and 8 in this chemical series for activity against Jak2, selectivity against other Jak family kinases, and good in vivo pharmacokinetic properties led to the discovery of 7j. In a SET2 xenograft model that is dependent on Jak2 for growth, 7j demonstrated a time-dependent knock-down of pSTAT5, a downstream target of Jak2.
PIK3CA is one of the most frequently mutated oncogenes; the p110α protein it encodes plays a central role in tumor cell proliferation. Small molecule inhibitors targeting the PI3K p110α catalytic subunit have entered clinical trials, with early-phase GDC-0077 studies showing antitumor activity and a manageable safety profile in patients with PIK3CA-mutant breast cancer.However, preclinical studies have shown that PI3K pathway inhibition releases negative feedback and activates receptor tyrosine kinase signaling, reengaging the pathway and attenuating drug activity. Here we discover that GDC-0077 and taselisib more potently inhibit mutant PI3K pathway signaling and cell viability through unique HER2-dependent mutant p110a degradation. Both are more effective than other PI3K inhibitors at maintaining prolonged pathway suppression. This study establishes a new strategy for identifying inhibitors that specifically target mutant tumors by selective degradation of the mutant oncoprotein and provide a strong rationale for pursuing PI3Kα degraders in patients with HER2-positive breast cancer.
SignificancePI3K inhibitors, GDC-0077 and taselisib, have unique mechanism of action; both inhibitors lead to degradation of mutant p110a protein. The inhibitors that have the ability to trigger specific degradation of mutant p110a without significant change in wildtype p110a protein may result in improved therapeutic index in PIK3CA mutant tumors.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.